Op-Ed: Commercial Demand in LEO Is Lacking. The Government Can Help.

Why It Matters

A thriving LEO manufacturing sector would secure U.S. leadership in high‑value space‑based products and protect national economic and security interests. Without government enablement, private capital will likely flow to Europe or China, eroding America’s strategic advantage.

Key Takeaways

• NASA moving from station funding to core module, signaling demand doubts.
• In-space manufacturing still lacks commercial orders despite biotech proof-of-concept.
• UK offers clear regulatory pathway; US FDA remains nascent.
• US captured <50% of global space VC in 2024, trailing Europe/China.
• Authors urge $50B private investment and inter‑agency policy to spark LEO economy.

Pulse Analysis

NASA’s recent budget shift—favoring a single core module over a full free‑flying station—signals a cautious stance on LEO demand. While launch costs have fallen and the ISS has demonstrated scientific value, private firms still see limited revenue streams for large‑scale manufacturing. This hesitancy is compounded by an absence of a coherent U.S. policy that ties research funding to commercial outcomes, leaving investors uncertain about long‑term returns.

In‑space manufacturing promises breakthroughs that terrestrial labs cannot achieve, from protein crystals that improve drug delivery to micro‑organs for disease modeling. The biotech sector, a $1.5 trillion market, has already benefited from ISS experiments, yet the pipeline to commercial products stalls without clear regulatory pathways. The United Kingdom’s cross‑government initiative, which aligns space, health, and civil aviation regulators, offers a template for accelerating approvals of space‑manufactured therapeutics. By contrast, the FDA’s nascent engagement leaves U.S. companies without a predictable route to market, dampening investment enthusiasm.

The authors call for a coordinated federal strategy that blends infrastructure funding, regulatory reform, and national‑security priorities. A $50 billion private‑investment goal, backed by inter‑agency coordination among NASA, the Department of Defense, HHS, and NSF, could catalyze a robust LEO industrial base. Failure to act risks ceding this emerging market to Europe and China, which together captured over half of global space venture capital in 2024. Prompt policy action would not only preserve U.S. leadership but also translate microgravity advantages into tangible health and economic benefits for Americans.